Endonovo Therapeutics, Inc. (ENDV)
USD 0.0
(14.29%)
USD 0.0
(14.29%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 7.07 Million USD | -1.12% |
| 2022 | 7.15 Million USD | -0.39% |
| 2021 | 7.18 Million USD | 8.25% |
| 2020 | 6.63 Million USD | -3.32% |
| 2019 | 6.86 Million USD | 8.5% |
| 2018 | 6.32 Million USD | 33.56% |
| 2017 | 4.73 Million USD | 129.35% |
| 2016 | 2.06 Million USD | 33.52% |
| 2015 | 1.54 Million USD | 9.19% |
| 2014 | 1.41 Million USD | 87.11% |
| 2013 | 756.88 Thousand USD | 163.12% |
| 2012 | 287.65 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 7.01 Million USD | -0.6% |
| 2024 Q1 | 7.05 Million USD | -0.2% |
| 2023 Q3 | 7.05 Million USD | 0.43% |
| 2023 Q2 | 7.02 Million USD | 1.84% |
| 2023 Q4 | 7.07 Million USD | 0.22% |
| 2023 FY | 7.07 Million USD | -1.12% |
| 2023 Q1 | 6.9 Million USD | -3.53% |
| 2022 Q1 | 7.29 Million USD | 1.56% |
| 2022 FY | 7.15 Million USD | -0.39% |
| 2022 Q4 | 7.15 Million USD | -1.2% |
| 2022 Q3 | 7.24 Million USD | -1.59% |
| 2022 Q2 | 7.35 Million USD | 0.87% |
| 2021 Q4 | 7.18 Million USD | 6.05% |
| 2021 FY | 7.18 Million USD | 8.25% |
| 2021 Q2 | 6.65 Million USD | -1.14% |
| 2021 Q1 | 6.73 Million USD | 1.54% |
| 2021 Q3 | 6.77 Million USD | 1.69% |
| 2020 Q4 | 6.63 Million USD | 8.73% |
| 2020 Q1 | 6.18 Million USD | -9.94% |
| 2020 FY | 6.63 Million USD | -3.32% |
| 2020 Q2 | 6.2 Million USD | 0.42% |
| 2020 Q3 | 6.1 Million USD | -1.69% |
| 2019 Q2 | 6.78 Million USD | 8.06% |
| 2019 Q1 | 6.27 Million USD | -0.77% |
| 2019 FY | 6.86 Million USD | 8.5% |
| 2019 Q3 | 7.13 Million USD | 5.18% |
| 2019 Q4 | 6.86 Million USD | -3.79% |
| 2018 FY | 6.32 Million USD | 33.56% |
| 2018 Q4 | 6.32 Million USD | -12.61% |
| 2018 Q3 | 7.23 Million USD | 17.99% |
| 2018 Q2 | 6.13 Million USD | 12.28% |
| 2018 Q1 | 5.46 Million USD | 15.35% |
| 2017 Q1 | 2 Million USD | -2.8% |
| 2017 Q2 | 2.37 Million USD | 18.57% |
| 2017 Q3 | 2.72 Million USD | 14.59% |
| 2017 Q4 | 4.73 Million USD | 73.66% |
| 2017 FY | 4.73 Million USD | 129.35% |
| 2016 Q3 | 1.89 Million USD | 15.49% |
| 2016 FY | 2.06 Million USD | 33.52% |
| 2016 Q4 | 2.06 Million USD | 8.78% |
| 2016 Q2 | 1.64 Million USD | 4.77% |
| 2016 Q1 | 1.56 Million USD | 1.44% |
| 2015 Q3 | 1.52 Million USD | 15.26% |
| 2015 Q1 | 1.33 Million USD | -5.99% |
| 2015 FY | 1.54 Million USD | 9.19% |
| 2015 Q4 | 1.54 Million USD | 1.59% |
| 2015 Q2 | 1.32 Million USD | -0.81% |
| 2014 Q3 | 1.24 Million USD | -10.4% |
| 2014 FY | 1.41 Million USD | 87.11% |
| 2014 Q4 | 1.41 Million USD | 14.21% |
| 2014 Q1 | 1.03 Million USD | 36.77% |
| 2014 Q2 | 1.38 Million USD | 33.71% |
| 2013 Q4 | 756.88 Thousand USD | 40.6% |
| 2013 FY | 756.88 Thousand USD | 163.12% |
| 2013 Q1 | 353.25 Thousand USD | 22.8% |
| 2013 Q2 | 490.12 Thousand USD | 38.75% |
| 2013 Q3 | 538.34 Thousand USD | 9.84% |
| 2012 Q4 | 287.65 Thousand USD | -78.21% |
| 2012 FY | 287.65 Thousand USD | 0.0% |
| 2012 Q1 | 1.16 Million USD | 25.27% |
| 2012 Q2 | 1.16 Million USD | 0.0% |
| 2012 Q3 | 1.32 Million USD | 13.3% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | 930 Thousand USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 82.834% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -71.589% |
| SQZ Biotechnologies Company | 27.47 Million USD | 74.254% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 83.693% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 76.24% |
| Mesoblast Limited | 118.7 Million USD | 94.041% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -645.864% |
| Genus plc | 233.1 Million USD | 96.966% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -141.361% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -426.414% |
| Marizyme, Inc. | 18.71 Million USD | 62.213% |
| ContraFect Corporation | 2.88 Million USD | -145.498% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -843.041% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -5120.287% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -389.021% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -204.082% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -24.998% |
| MultiCell Technologies, Inc. | 202.58 USD | -3491266.374% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 87.697% |
| EV Biologics, Inc. | 1.49 Million USD | -373.176% |
| Q BioMed Inc. | 4.1 Million USD | -72.089% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 78.633% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -1022.531% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -475.792% |
| Biomind Labs Inc. | 735.54 Thousand USD | -861.578% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 95.877% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 45.581% |
| Skye Bioscience, Inc. | 4.61 Million USD | -53.248% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -696.43% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -4897.817% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -20.468% |
| IMV Inc. | 28.88 Million USD | 75.513% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -27400.33% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -213.181% |
| GB Sciences, Inc. | 1.75 Million USD | -302.023% |
| Alpha Cognition Inc. | 1.22 Million USD | -479.562% |
| HST Global, Inc. | 98.31 Thousand USD | -7093.737% |
| CSL Limited | 12.18 Billion USD | 99.942% |
| Halberd Corporation | 150 Thousand USD | -4615.207% |
| Enzolytics Inc. | 996.33 Thousand USD | -609.881% |
| Resverlogix Corp. | 6.49 Million USD | -8.963% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -1381.217% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -2667.227% |
| argenx SE | 20 Million USD | 64.636% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 84.476% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -161.114% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -69071.736% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.307% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -3425.546% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -194.98% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -2984.644% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 89.544% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -133.72% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1866.253% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 65.207% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -4657.901% |
| BioStem Technologies, Inc. | 4.71 Million USD | -50.121% |
| ONE Bio Corp. | 19.71 Million USD | 64.125% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -2727.066% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -2743.684% |
| Agentix Corp. | 50 Thousand USD | -14045.62% |
| LadRx Corporation | 33.6 Thousand USD | -20946.271% |
| Cell Source, Inc. | 9.25 Million USD | 23.572% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -835.304% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -835.304% |
| NovAccess Global Inc. | 2.19 Million USD | -221.509% |
| Itoco Inc. | 228.37 Thousand USD | -2996.989% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -3252.44% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -41.939% |
| Kadimastem Ltd | 891.22 Thousand USD | -693.605% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1660.067% |
| CytoDyn Inc. | 30.07 Million USD | 76.484% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -1360.467% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1910.195% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 9.554% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -5673.722% |
| Rebus Holdings, Inc. | 310 Thousand USD | -2181.552% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -49.364% |
| International Stem Cell Corporation | 4.17 Million USD | -69.287% |
| Bioxytran, Inc. | 1.92 Million USD | -267.419% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -11232.271% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -224.307% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 14.949% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 17.614% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -354.703% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -2539.108% |
| Neutra Corp. | 54.15 Thousand USD | -12960.067% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -286.492% |
| PureTech Health plc | 25.51 Million USD | 72.277% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -477.737% |
| IXICO plc | 472.02 Thousand USD | -1398.404% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 54.372% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 88.64% |
| CSL Limited | 12.18 Billion USD | 99.942% |
| Cellectis S.A. | 92.77 Million USD | 92.377% |